Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)

ReutersJun 25, 2025 12:24 PM

June 25 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O:

AMNEAL HIGHLIGHTS POSITIVE TOPLINE RESULTS FROM CONFIRMATORY CLINICAL STUDY OF BIOSIMILAR CANDIDATE TO XOLAIR(R) (OMALIZUMAB), DEVELOPED BY KASHIV BIOSCIENCES
AMNEAL PHARMACEUTICALS INC - ADL-018 CLINICAL STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS
AMNEAL PHARMACEUTICALS INC - BLA FOR ADL-018 EXPECTED TO BE SUBMITTED TO FDA IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Intel Just Hit $94.75 While the Nasdaq Fell — and Institutions Are Still Buying. Is INTC a Buy?

Intel Corporation (NASDAQ: INTC) closed the day at $94.75, notching a second consecutive +12.10% day, and is now up a total +40.43% over the past five days. The key difference between Wednesday's action and the post-earnings party over the past week is this: Intel's volume on Wednesday was 227.3 mil

Is Lululemon Stock a Buy or a Risky Bet Amidst Financial Pressure and Management Changes?

TradingKey - An athleisure company, Lululemon Athletica（LULU）, has built a very successful niche in the fashionable athletic wear category.

Featured Tools

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)

Recommended Articles

Intel Just Hit $94.75 While the Nasdaq Fell — and Institutions Are Still Buying. Is INTC a Buy?

Can Robinhood Stock Surge Again in 2026?

Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

VOO Stock Price: Is the S&P 500 ETF Still the Smarter Buy vs QQQ?

Is Lululemon Stock a Buy or a Risky Bet Amidst Financial Pressure and Management Changes?